Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation

Current Opinion in Chemical Biology

Volumn 33, Issue , 2016, Pages 160-168

  Leus, Niek G J ^a   Zwinderman, Martijn R H ^a   Dekker, Frank J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 3 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; RGFP 966; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; INFLAMMATION; MEDICINAL CHEMISTRY; NONHUMAN; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INFLAMMATION; NF-KAPPA B;

EID: 84976428039     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2016.06.019     Document Type: Review

References (84)

1. Medzhitov R., Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol 2009, 9:692-703.
2. Choudhary C., Weinert B.T., Nishida Y., Verdin E., Mann M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol 2014, 15:536-550.
3. Dekker F.J., van den Bosch T., Martin N.I. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases. Drug Discov Today 2014, 19:654-660.
4. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
5. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
6. Gunawardhana L.P., Gibson P.G., Simpson J.L., Powell H., Baines K.J. Activity and expression of histone acetylases and deacetylases in inflammatory phenotypes of asthma. Clin Exp Allergy 2014, 44:47-57.
7. Ito K., Caramori G., Lim S., Oates T., Chung K.F., Barnes P.J., Adcock I.M. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002, 166:392-396.
8. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
9. Scholz C., Weinert B.T., Wagner S.A., Beli P., Miyake Y., Qi J., Jensen L.J., Streicher W., McCarthy A.R., Westwood N.J., et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol 2015, 33:415-423.
10. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010, 6:238-243.
11. Bantscheff M., Hopf C., Savitski M.M., Dittmann A., Grandi P., Michon A.M., Schlegl J., Abraham Y., Becher I., Bergamini G., et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011, 29:255-265.
12. Salisbury C.M., Cravatt B.F. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci U S A 2007, 104:1171-1176.
13. Spange S., Wagner T., Heinzel T., Kramer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009, 41:185-198.
14. Chen L.F., Mu Y., Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 2002, 21:6539-6548.
15. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001, 293:1653-1657.
16. Ito K. Impact of post-translational modifications of proteins on the inflammatory process. Biochem Soc Trans 2007, 35:281-283.
17. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008, 9:206-218.
18. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370:737-749.
19. Parra M., Verdin E. Regulatory signal transduction pathways for class IIa histone deacetylases. Curr Opin Pharmacol 2010, 10:454-460.
20. Dali-Youcef N., Lagouge M., Froelich S., Koehl C., Schoonjans K., Auwerx J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med 2007, 39:335-345.
21. Horiuchi M., Morinobu A., Chin T., Sakai Y., Kurosaka M., Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009, 36:1580-1589.
22. Gopal Y.N., Van Dyke M.W. Depletion of histone deacetylase protein: a common consequence of inflammatory cytokine signaling?. Cell Cycle 2006, 5:2738-2743.
23. Grausenburger R., Bilic I., Boucheron N., Zupkovitz G., El-Housseiny L., Tschismarov R., Zhang Y., Rembold M., Gaisberger M., Hartl A., et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol 2010, 185:3489-3497.
24. Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009, 71:451-464.
25. Ahmad T., Barnes P.J., Adcock I.M. Overcoming steroid insensitivity in smoking asthmatics. Curr Opin Investig Drugs 2008, 9:470-477.
26. Inoue K., Kobayashi M., Yano K., Miura M., Izumi A., Mataki C., Doi T., Hamakubo T., Reid P.C., Hume D.A., et al. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler Thromb Vasc Biol 2006, 26:2652-2659.
27. Kim Y., Kim K., Park D., Lee E., Lee H., Lee Y.S., Choe J., Jeoung D. Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein. J Biol Chem 2012, 287:25844-25859.
28. Winkler A.R., Nocka K.N., Williams C.M. Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production. Pulm Pharmacol Ther 2012, 25:286-292.
29. Mullican S.E., Gaddis C.A., Alenghat T., Nair M.G., Giacomin P.R., Everett L.J., Feng D., Steger D.J., Schug J., Artis D., Lazar M.A. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev 2011, 25:2480-2488.
30. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004, 5:392-401.
31. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009, 1:a001651.
32. Wisastra R., Dekker F.J. Inflammation, cancer and oxidative lipoxygenase activity are intimately linked. Cancers (Basel) 2014, 6:1500-1521.
33. Ghizzoni M., Haisma H.J., Maarsingh H., Dekker F.J. Histone acetyltransferases are crucial regulators in NF-kappaB mediated inflammation. Drug Discov Today 2011, 16:504-511.
34. Huang B., Yang X.D., Lamb A., Chen L.F. Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal 2010, 22:1282-1290.
35. Buerki C., Rothgiesser K.M., Valovka T., Owen H.R., Rehrauer H., Fey M., Lane W.S., Hottiger M.O. Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. Nucleic Acids Res 2008, 36:1665-1680.
36. Chen L.F., Williams S.A., Mu Y., Nakano H., Duerr J.M., Buckbinder L., Greene W.C. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005, 25:7966-7975.
37. Ziesche E., Kettner-Buhrow D., Weber A., Wittwer T., Jurida L., Soelch J., Muller H., Newel D., Kronich P., Schneider H., et al. The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-kappaB. Nucleic Acids Res 2013, 41:90-109.
38. Chen X., Barozzi I., Termanini A., Prosperini E., Recchiuti A., Dalli J., Mietton F., Matteoli G., Hiebert S., Natoli G. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci U S A 2012, 109:E2865-E2874.
39. Zhu H., Shan L., Schiller P.W., Mai A., Peng T. Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation. J Biol Chem 2010, 285:9429-9436.
40. Mohapatra D.K., Reddy D.S., Ramaiah M.J., Ghosh S., Pothula V., Lunavath S., Thomas S., Valli S.N., Bhadra M.P., Yadav J.S. Rugulactone derivatives act as inhibitors of NF-kappaB activation and modulates the transcription of NF-kappaB dependent genes in MDA-MB-231cells. Bioorg Med Chem Lett 2014, 24:1389-1396.
41. Fischer A. Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?. Neuropharmacology 2014, 80:95-102.
42. Royce S.G., Karagiannis T.C. Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions. Curr Opin Allergy Clin Immunol 2014, 14:44-48.
43. Grabiec A.M., Tak P.P., Reedquist K.A. Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol 2011, 31:233-263.
44. Wightman F., Ellenberg P., Churchill M., Lewin S.R. HDAC inhibitors in HIV. Immunol Cell Biol 2012, 90:47-54.
45. Dinarello C.A., Fossati G., Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 2011, 17:333-352.
46. Halili M.A., Andrews M.R., Labzin L.I., Schroder K., Matthias G., Cao C., Lovelace E., Reid R.C., Le G.T., Hume D.A., et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010, 87:1103-1114.
47. Nasu Y., Nishida K., Miyazawa S., Komiyama T., Kadota Y., Abe N., Yoshida A., Hirohata S., Ohtsuka A., Ozaki T. Trichostatin A a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthr Cartil 2008, 16:723-732.
48. Grabiec A.M., Korchynskyi O., Tak P.P., Reedquist K.A. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012, 71:424-431.
49. Furlan A., Monzani V., Reznikov L.L., Leoni F., Fossati G., Modena D., Mascagni P., Dinarello C.A. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 2011, 17:353-362.
50. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., Dona G., Fossati G., Sozzani S., Azam T., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 2002, 99:2995-3000.
51. Imre G., Gekeler V., Leja A., Beckers T., Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006, 66:5409-5418.
52. Yu Z., Zhang W., Kone B.C. Histone deacetylases augment cytokine induction of the iNOS gene. J Am Soc Nephrol 2002, 13:2009-2017.
53. Grabiec A.M., Krausz S., de Jager W., Burakowski T., Groot D., Sanders M.E., Prakken B.J., Maslinski W., Eldering E., Tak P.P., Reedquist K.A. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010, 184:2718-2728.
54. Zhang Q., Yang F., Li X., Wang L.W., Chu X.G., Zhang H., Gong Z.J. Trichostatin A protects against experimental acute-on-chronic liver failure in rats through regulating the acetylation of nuclear factor-kappaB. Inflammation 2015, 38:1364-1373.
55. Sato T., Kotake D., Hiratsuka M., Hirasawa N. Enhancement of inflammatory protein expression and nuclear factor Kappab (NF-Kappab) activity by trichostatin A (TSA) in OP9 preadipocytes. PLoS ONE 2013, 8:e59702.
56. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409:581-589.
57. Rosato R.R., Kolla S.S., Hock S.K., Almenara J.A., Patel A., Amin S., Atadja P., Fisher P.B., Dent P., Grant S. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 2010, 285:10064-10077.
58. Leoni F., Fossati G., Lewis E.C., Lee J.K., Porro G., Pagani P., Modena D., Moras M.L., Pozzi P., Reznikov L.L., et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005, 11:1-15.
59. Faraco G., Pittelli M., Cavone L., Fossati S., Porcu M., Mascagni P., Fossati G., Moroni F., Chiarugi A. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis 2009, 36:269-279.
60. Chung Y.L., Lee M.Y., Wang A.J., Yao L.F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003, 8:707-717.
61. Marson C.M., Matthews C.J., Yiannaki E., Atkinson S.J., Soden P.E., Shukla L., Lamadema N., Thomas N.S. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit. J Med Chem 2013, 56:6156-6174.
62. Vojinovic J., Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 2011, 17:397-403.
63. Wang H., Cheng F., Woan K., Sahakian E., Merino O., Rock-Klotz J., Vicente-Suarez I., Pinilla-Ibarz J., Wright K.L., Seto E., et al. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol 2011, 186:3986-3996.
64. Dai Y., Rahmani M., Dent P., Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005, 25:5429-5444.
65. Tang J., Cho N.W., Cui G., Manion E.M., Shanbhag N.M., Botuyan M.V., Mer G., Greenberg R.A. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol 2013, 20:317-325.
66. Zhang Z.Y., Schluesener H.J. HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis. Prostate 2012, 72:90-99.
67. Lin H.S., Hu C.Y., Chan H.Y., Liew Y.Y., Huang H.P., Lepescheux L., Bastianelli E., Baron R., Rawadi G., Clement-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007, 150:862-872.
68. Choo Q.Y., Ho P.C., Tanaka Y., Lin H.S. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford) 2010, 49:1447-1460.
69. Gillespie J., Savic S., Wong C., Hempshall A., Inman M., Emery P., Grigg R., McDermott M.F. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 2012, 64:418-422.
70. Choi Y., Park S.K., Kim H.M., Kang J.S., Yoon Y.D., Han S.B., Han J.W., Yang J.S., Han G. Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp Mol Med 2008, 40:574-581.
71. Morioka N., Tomori M., Zhang F.F., Saeki M., Hisaoka-Nakashima K., Nakata Y. Stimulation of nuclear receptor REV-ERBs regulates tumor necrosis factor-induced expression of proinflammatory molecules in C6 astroglial cells. Biochem Biophys Res Commun 2016, 469:151-157.
72. Leus N.G., van der Wouden P.E., van den Bosch T., Hooghiemstra W.T., Ourailidou M.E., Kistemaker L.E., Bischoff R., Gosens R., Haisma H.J., Dekker F.J. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-kappaB p65 transcriptional activity. Biochem Pharmacol 2016, 108:58-74.
73. Suzuki T., Kasuya Y., Itoh Y., Ota Y., Zhan P., Asamitsu K., Nakagawa H., Okamoto T., Miyata N. Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS ONE 2013, 8:e68669.
74. Micelli C., Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today 2015, 20:718-735.
75. Chou C.J., Herman D., Gottesfeld J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 2008, 283:35402-35409.
76. Yao Y., Liao C., Li Z., Wang Z., Sun Q., Liu C., Yang Y., Tu Z., Jiang S. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. Eur J Med Chem 2014, 86:639-652.
77. Thaler F., Moretti L., Amici R., Abate A., Colombo A., Carenzi G., Fulco M.C., Boggio R., Dondio G., Gagliardi S., et al. Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. Eur J Med Chem 2016, 108:53-67.
78. Fraczek J., Vanhaecke T., Rogiers V. Toxicological and metabolic considerations for histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol 2013, 9:441-457.
79. Wambua M.K., Nalawansha D.A., Negmeldin A.T., Pflum M.K. Mutagenesis studies of the 14 A internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design. J Med Chem 2014, 57:642-650.
80. Methot J.L., Chakravarty P.K., Chenard M., Close J., Cruz J.C., Dahlberg W.K., Fleming J., Hamblett C.L., Hamill J.E., Harrington P., et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008, 18:973-978.
81. Chen K., Xu L., Wiest O. Computational exploration of zinc binding groups for HDAC inhibition. J Org Chem 2013, 78:5051-5055.
82. Lobera M., Madauss K.P., Pohlhaus D.T., Wright Q.G., Trocha M., Schmidt D.R., Baloglu E., Trump R.P., Head M.S., Hofmann G.A., et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol 2013, 9:319-325.
83. Bertino E.M., Otterson G.A. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011, 20:1151-1158.
84. Ueda H., Nakajima H., Hori Y., Fujita T., Nishimura M., Goto T., Okuhara M. FR901228 a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994, 47:301-310.